Reviva prices $5.0M at-the-market offering of common stock and warrants

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Offering comprises 4,761,905 shares (or pre-funded warrants) plus warrants for same number; combined price $1.05 per unit.
Warrants exercisable at $0.7964/share, expire 5 years from issuance; pre-funded warrants at $0.0001/share.
Existing warrants for up to 4,736,561 shares amended to $0.7964 exercise price and 5-year term for $0.125 per warrant.
Net proceeds expected to fund Phase 3 RECOVER-2 trial and working capital; gross proceeds ~$5.0M.
Titan Partners Group is sole bookrunner; closing expected August 22, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.